Health experts are warning that a new "super gonorrhoea" could prove impossible to treat after the number of cases of the sexually transmitted infection hit a record high. Data from the UK Health ...

GSK (NYSE:GSK) announced on Monday positive headline results from a pivotal late-stage trial of its gonorrhoea drug, gepotidacin. The EAGLE-1 phase III trial met its primary efficacy endpoint of ...

Innoviva has moved a step closer to bringing the first novel antibiotic to market for gonorrhoea in decades after reporting positive results in a phase 3 trial. An oral dose of zoliflodacin ...

GSK has unveiled the data for its novel antibiotic gepotidacin as a treatment for gonorrhoea, putting the drug on track to become an important therapy for people with resistant forms of the ...

Experts attribute the rise of drug-resistant gonorrhoea to several factors that include the overuse and misuse of antibiotics ...

England is seeing record high levels of gonorrhoea and syphilis sexually transmitted infections, following a dip during Covid years, new figures reveal. People are being urged to practise safe sex ...

The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a mem ...

England has continued to see a rise in cases of syphilis and gonorrhoea over the past year. New data shows a 20% increase in cases of syphilis and a 22% increase in gonorrhoea, compared with 2016.

Newly-released health data shows a huge rise in cases of syphillis in the North East between 2022 and 2023. The region saw a 45% jump in cases, according to the UK Health Security Agency. That saw a ...

Leveraging gold-standard PCR technology, the cobas liat system claims to deliver outcomes in under 20 minutes.

Rising rates of gonorrhoea in the district cause alarm, and Trixie cares for an unmarried first-time mother recently diagnosed with a mental health condition.

GENEVA & LAUSANNE, Switzerland, January 14, 2025--(BUSINESS WIRE)--The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm ...